|
Index of reports
> Cases with Sepsis (114)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include sepsis. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 114 Next >>
Possible Vincristine side effects in 18 year old female
Reported by a physician from Slovenia on 2012-08-23
Patient: 18 year old female
Reactions: Pulmonary Haemorrhage, Gastrointestinal Haemorrhage, Injection Site Haemorrhage, Sepsis, Shock Haemorrhagic, Acute Respiratory Distress Syndrome, Bone Marrow Failure, Staphylococcal Bacteraemia, Septic Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Heparin
Vincristine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-21
Patient: male, weighing 115.7 kg (254.5 pounds)
Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Cyclophosphamide
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Prednisone TAB
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Remicade
Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
Indication: Rheumatoid Arthritis
Start date: 2001-10-01
End date: 2006-06-29
Vincristine
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Other drugs received by patient: Azulfadine; Lisinopril
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Off Label Use, Sepsis, Cerebral Ischaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: on day 1 over 15-30 minutes
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Sepsis, Hypoxia, Pleural Effusion
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Sepsis, Hypoxia
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-14
Patient:
Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: on day 1 over 15-30 minutes
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient:
Reactions: Sepsis, Diffuse Large B-Cell Lymphoma Recurrent, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin
Dosage: days 1 and 5
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: patients on r-chop received 750 mg/m2 on day 1; and acvbp received 1200 mg/m2
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: day 1,patients on r-chop recieved 50 mg/m2; and on acvbp received 75 mg/m2 on day 1
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: days 1 through 5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: day 1, in r-chop regimen
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: day 1 in r-chop regimen
Indication: Diffuse Large B-Cell Lymphoma
Vindesine
Dosage: days 1 and 5
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Fluorodeoxyglucose F 18
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-31
Patient:
Reactions: Neutropenic Sepsis, Sepsis, Dyspraxia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: B-Cell Lymphoma
Prednisolone
Dosage: on day 1-5
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-27
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Doxorubicin Hydrochloride
Prednisone
Indication: B-Cell Lymphoma
Rituximab
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Rituxan
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Vincristine side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 300 mg/m2
Cyclophosphamide
Dosage: 250 mg/m2, bid for six doses
Indication: non-Hodgkin's Lymphoma
Cytarabine
Dosage: 100 mg/m2, daily x 5 days
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 30 mg/m2, single
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: 60 mg/m2, single
Hydrocortisone Acetate
Dosage: given with methotrexate
Indication: non-Hodgkin's Lymphoma
Hydrocortisone Acetate
Dosage: given with cytarabine
Methotrexate
Dosage: 3000 mg/m2, single
Methotrexate
Dosage: given with hydrocortisone twice x 2
Indication: non-Hodgkin's Lymphoma
Methotrexate
Dosage: 1500 mg/m2, single
Prednisolone
Dosage: 60 mg/m2, daily for 5 days then tapered over 3 days
Indication: non-Hodgkin's Lymphoma
Prednisolone
Dosage: 60 mg/m2, daily for 7 days
Rituximab
Dosage: 1875 mg/m2, every 2-4 weeks for 5 total doses
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: 2 mg/m2, single
Vincristine
Dosage: 1 mg/m2, single
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in 18 month old male
Reported by a physician from United States on 2012-07-06
Patient: 18 month old male, weighing 11.4 kg (25.1 pounds)
Reactions: Sepsis, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Dexamethasone Sodium Phosphate
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Dexamethasone Sodium Phosphate
Etoposide
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Lestaurtinib
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Lestaurtinib
Mercaptopurine
Mercaptopurine
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Methotrexate
Vincristine
Vincristine
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-04-18
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Vincristine side effects in 14 year old female
Reported by a physician from United States on 2012-06-28
Patient: 14 year old female, weighing 60.4 kg (132.9 pounds)
Reactions: Stomatitis, Hypotension, Encephalopathy, Acidosis, Hypercalcaemia, Respiratory Failure, Sepsis, Posterior Reversible Encephalopathy Syndrome, Hypocalcaemia, Enterocolitis, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Ambisome
Dosage: unk
Indication: Candida Test Positive
Start date: 2012-05-20
Calcium Gluconate
Cefepime
Dosage: unk
Indication: Klebsiella Infection
Start date: 2012-05-10
Dexamethasone Sodium Phosphate
Dosage: 10 mg/m2, bid or iv on days 1-5 and 15-19
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Methotrexate
Dosage: 8-15 mg (age based dosing) it on days 1 (or up to 72 hours prior to day 1) and 8
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Mitoxantrone Hydrochloride
Dosage: 10 mg/m2, over 30 minutes on days 1 and 2
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Pegaspargase
Dosage: 2500 iu/m2 over 1 hr on days 3 and 17
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Temsirolimus
Dosage: 7.5 mg/m2, over 30 minutes on days i, 8 and 15 (max dose: 15 mg)
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Vincristine
Dosage: 1.5 mg/m2 cyclic (max 2 mg) over i-5 minutes or infusion via mini bag on days 1, 8, i5 and 22
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-06-26
Patient: female
Reactions: Syncope, Sepsis, Hypotension, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1493 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Rituximab
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Vincristine
Dosage: 3.94 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Simvastatin; Levothyroxine; Ramipril; Acyclovir; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Torsemide; Pantoprazole; Nebivolol
Possible Vincristine side effects in 16 month old female
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-26
Patient: 16 month old female
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Carboplatin
Dosage: 10 mg/kg daily on days 0
Indication: Brain Neoplasm Malignant
Cisplatin
Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
Indication: Brain Neoplasm Malignant
Cyclophosphamide
Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)
Etoposide
Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Ifosfamide
Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
Indication: Brain Neoplasm Malignant
Vincristine
Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
Indication: Brain Neoplasm Malignant
Possible Vincristine side effects in 16 month old female
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-25
Patient: 16 month old female
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Carboplatin
Dosage: 10 mg/kg daily on days 0
Indication: Brain Neoplasm Malignant
Cisplatin
Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
Indication: Brain Neoplasm Malignant
Cyclophosphamide
Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
Indication: Brain Neoplasm Malignant
Etoposide
Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)
Ifosfamide
Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
Indication: Brain Neoplasm Malignant
Vincristine
Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
Indication: Brain Neoplasm Malignant
Possible Vincristine side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Possible Vincristine side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Methotrexate
Dosage: 3000 mg/m2; administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Possible Vincristine side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Possible Vincristine side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-20
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Pancytopenia, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 250 mg/m2, bid for 6 doses
Cyclophosphamide
Dosage: 250 mg/m2, bid for 6 doses
Cyclophosphamide
Dosage: 300 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: 100 mg/m2, for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: unknown
Doxorubicin HCL
Dosage: 30 mg/m2, unk
Doxorubicin HCL
Dosage: 60 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Dosage: intrathecally twice
Hydrocortisone
Hydrocortisone
Dosage: intrathecally twice
Hydrocortisone
Dosage: unknwon
Methotrexate
Dosage: 1500 mg/m2, unk
Methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: intrathecally twice
Methotrexate
Dosage: intrathecally twice
Methotrexate
Dosage: 1500 mg/m2, unk
Methotrexate
Dosage: 30000 mg/m2, unk
Methotrexate
Prednisolone
Dosage: 60 mg/m2, for 5 days, then taper over 3 days
Prednisolone
Dosage: 60 mg/m2, for 5 days then taper over 3 days
Prednisolone
Dosage: 60 mg/m2, per day for 7 days
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: every 2-4 weeks for 5 total doses with cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: cumulative dose of 1875 mg/m2
Vincristine
Dosage: 2 mg/m2, unk
Vincristine
Dosage: 1 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: 1 mg/m2, unk
Possible Vincristine side effects in male
Reported by a physician from Italy on 2012-06-14
Patient: male
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Other drugs received by patient: Unknown Medication
Possible Vincristine side effects in 68 year old male
Reported by a individual with unspecified qualification from Chile on 2012-06-05
Patient: 68 year old male
Reactions: Rectal Haemorrhage, Sepsis, Pancytopenia, Neutropenia, Ascites
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclosporine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Methylprednisolone
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04
Patient:
Reactions: Sepsis, Toxicity To Various Agents
Adverse event resulted in: death
Drug(s) suspected as cause:
Elspar
Indication: Lymphocytic Leukaemia
Methotrexate
Dosage: intrathecal
Indication: Acute Lymphocytic Leukaemia
Prednisolone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Elspar
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: intrathecal
Indication: Acute Lymphocytic Leukaemia
Prednisolone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-04
Patient:
Reactions: Sepsis, Toxicity To Various Agents
Adverse event resulted in: death
Drug(s) suspected as cause:
Elspar
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: intrathecal
Indication: Acute Lymphocytic Leukaemia
Prednisolone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Page 1 Next >>
|
